6 September 2016 - Patients in England and Wales with melanoma will not be getting routine access to Roche's Cotellic/Zelboraf combination on the NHS, after it was turned down by NICE.

NICE has published final guidance rejecting use of Cotellic (cobimetinib hemifumarate) with Zelboraf (vemurafenib) for people with advanced BRAF V600 mutation-positive melanoma that has spread and can't be surgically removed, after concluding that it would not represent a cost-effective use of resources.

Read Pharma Times article